In 2017, there have been substantial advances in our understanding of the immunological and endocrine mechanisms of disease progression in NAFLD, paving the way for novel therapeutic strategies.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Mutual interaction between endoplasmic reticulum and mitochondria in nonalcoholic fatty liver disease
Lipids in Health and Disease Open Access 13 April 2020
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease — meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73–84 (2016).
Wong, R. J. et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 148, 547–555 (2015).
Luedde, T., Kaplowitz, N. & Schwabe, R. F. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology,147 765–783.e4 (2014).
Guo, L. et al. Hepatic neuregulin 4 signaling defines an endocrine checkpoint for steatosis-to-NASH progression. J. Clin. Invest. 127, 4449–4461 (2017).
Jiang, J. et al. Circulating neuregulin 4 levels are inversely associated with subclinical cardiovascular disease in obese adults. Sci. Rep. 6, 36710 (2016).
Hart, K. M. et al. Type 2 immunity is protective in metabolic disease but exacerbates NAFLD collaboratively with TGF-β. Sci. Transl Med. 9, 396 (2017).
Majumdar, A. et al. Hepatic stem cells and transforming growth factor beta in hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 9, 530–538 (2012).
Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcioma. N. Engl. J. Med, 359, 378–390 (2008).
Shalapour, S. et al. Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature 551, 340–345 (2017).
El-Khoueiry, A. B. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389, 2492–2502 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
P.N.N. has served as a speaker, a consultant and an advisory board member for AbbVie, Boehringer Ingelheim, Gilead, Intercept, Janssen, Novartis, Novo Nordisk, Pharmaxis and Shire, and has received research funding from these organizations on behalf of the University of Birmingham, UK. R.S.K. has received research funding from the National Institute of Health Research.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Khan, R., Newsome, P. Novel insights into mechanisms of disease progression. Nat Rev Gastroenterol Hepatol 15, 71–72 (2018). https://doi.org/10.1038/nrgastro.2017.181
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2017.181
This article is cited by
-
Role of Akkermansia muciniphila in the development of nonalcoholic fatty liver disease: current knowledge and perspectives
Frontiers of Medicine (2022)
-
Mutual interaction between endoplasmic reticulum and mitochondria in nonalcoholic fatty liver disease
Lipids in Health and Disease (2020)
-
Diagnose und Verlaufsbeurteilung von Fettlebererkrankungen
Der Gastroenterologe (2018)